{"id":"sar302503","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1287853","moleculeType":"Small molecule","molecularWeight":"524.69"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the PD-1 receptor, SAR302503 allows T cells to recognize and target cancer cells more effectively, leading to an enhanced anti-tumor immune response. This mechanism of action is thought to be responsible for the drug's therapeutic effects in various types of cancer.","oneSentence":"SAR302503 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells, thereby enhancing the immune system's ability to recognize and attack cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:30.222Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Melanoma"}]},"trialDetails":[{"nctId":"NCT04282187","phase":"PHASE2","title":"Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2020-03-24","conditions":"Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome","enrollment":25},{"nctId":"NCT01836705","phase":"PHASE1","title":"Effect of SAR302503 on ECG Activity in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-05","conditions":"Neoplasm Malignant","enrollment":60},{"nctId":"NCT01420783","phase":"PHASE2","title":"Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-10","conditions":"Hematopoietic Neoplasm","enrollment":81},{"nctId":"NCT00724334","phase":"PHASE1, PHASE2","title":"A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-07","conditions":"Myelofibrosis","enrollment":42},{"nctId":"NCT01762462","phase":"PHASE1","title":"Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-12","conditions":"Hepatic Impairment","enrollment":17},{"nctId":"NCT01420770","phase":"PHASE2","title":"Phase 2 Study of SAR302503 in Patients With Myelofibrosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-08","conditions":"Hematopoietic Neoplasm","enrollment":30},{"nctId":"NCT01437787","phase":"PHASE3","title":"Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12","conditions":"Hematopoietic Neoplasm","enrollment":289},{"nctId":"NCT01523171","phase":"PHASE2","title":"Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-04","conditions":"Hematopoietic Neoplasm","enrollment":97},{"nctId":"NCT01585623","phase":"PHASE1","title":"Drug Interaction Study of SAR302503 in Patients With Solid Tumor","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-06","conditions":"Solid Tumor","enrollment":16},{"nctId":"NCT01692366","phase":"PHASE2","title":"Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-11","conditions":"Myelofibrosis","enrollment":8},{"nctId":"NCT01763190","phase":"PHASE1","title":"Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-11","conditions":"Renal Impairment","enrollment":36},{"nctId":"NCT03723148","phase":"","title":"Individual Patient Compassionate Use of Fedratinib","status":"AVAILABLE","sponsor":"Celgene","startDate":"","conditions":"Myelofibrosis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SAR302503","genericName":"SAR302503","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SAR302503 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells, thereby enhancing the immune system's ability to recognize and attack cancer cells. Used for Non-small cell lung cancer, Melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}